Fig. 3From: Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trialOxygenation changes (SPO2/FIO2 ratio) in the control and intervention groups during the studyBack to article page